|
Characteristic
|
Number
|
Percent
|
|---|
|
Total
|
375
|
100
|
|
Median age (yr)
|
71 (51–92)
| |
|
≤ 70 yr
|
185
|
49.3
|
|
> 70 yr
|
190
|
50.7
|
|
T stage
|
|
T1-T2
|
261
|
69.6
|
|
T3-T4
|
103
|
27.5
|
|
Unknown
|
11
|
2.9
|
|
NCCN risk group
|
|
Intermediate
|
143
|
38.1
|
|
High
|
232
|
61.9
|
|
Gleason Score
|
|
< 8
|
241
|
64.3
|
|
8–10
|
133
|
35.5
|
|
Unknown
|
1
|
0.3
|
|
PSA on presentation
|
|
≤ 20 ng/ml
|
253
|
67.5
|
|
> 20 ng/ml
|
118
|
31.5
|
|
Unknown
|
4
|
1
|
|
Median ADT duration (months)
|
10 (3–36)
|
–
|
|
Median Radiation Dose (Gy)
|
72 (70–78)
|
–
|
|
< 72
|
44
|
11.7
|
|
≥ 72
|
327
|
87.2
|
|
Unknown
|
4
|
1.1
|
-
NCCN National Comprehensive Cancer Network, ADT androgen deprivation therapy, PSA Prostate-Specific Antigen
